Showing results (91-100 of 103) with videos related to

Sort By:
Pageof 11
Cancer Cell|December 16, 2014
Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodiesAnn L White, H T Claude Chan, Ruth R French, et al.
The Journal of Pathology. Clinical Research|June 28, 2016
The prognosis of <i>MYC</i> translocation positive diffuse large B-cell lymphoma depends on the second hitAlexandra Clipson, Sharon Barrans, Naiyan Zeng, et al.
The Lancet. Oncology|April 6, 2019
Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trialAndrew Davies, Thomas E Cummin, Sharon Barrans, et al.
Leukemia|January 6, 2024
Non-IG::MYC in diffuse large B-cell lymphoma confers variable genomic configurations and MYC transactivation potentialChunye Zhang, Ellen Stelloo, Sharon Barrans, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 30, 2015
Development and Characterization of Monoclonal Antibodies Specific for Mouse and Human Fcγ ReceptorsAlison L Tutt, Sonya James, Stéphanie A Laversin, et al.
ESMO Open|September 21, 2018
Somatic cancer genetics in the UK: real-world data from phase I of the Cancer Research UK Stratified Medicine ProgrammeColin R Lindsay, Emily C Shaw, Fiona Blackhall, et al.
Immunity|November 18, 2018
Antibodies to Costimulatory Receptor 4-1BB Enhance Anti-tumor Immunity via T Regulatory Cell Depletion and Promotion of CD8 T Cell Effector FunctionSarah L Buchan, Lang Dou, Marcus Remer, et al.
Cancer Cell|April 16, 2015
Antagonistic human FcγRIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivoAli Roghanian, Ingrid Teige, Linda Mårtensson, et al.
British Journal of Haematology|November 17, 2024
Greater preservation of SARS-CoV-2 neutralising antibody responses following the ChAdOx1-S (AZD1222) vaccine compared with mRNA vaccines in haematopoietic cell transplant recipientsHayley Colton, Natalie Barratt, Nigel Temperton, et al.
Blood|September 12, 2025
Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trialEmanuele Zucca, Luca Ceriani, Giovannino Ciccone, et al.
Pageof 11